Salvage Chemotherapy in Recurrent Ovarian Cancer: a Combination of Gemcitabine and Treosulfan is Equally Active in Platinum-Resistant and Platinum-Sensitive Disease

Salvage Chemotherapy ◽

Platinum Sensitive ◽

Is it time to change the primary endpoint in clinical trials in recurrent ovarian cancer (ROC)?: Symptom burden and outcomes in patients with platinum resistant/refractory (PRR) and potentially platinum sensitive ROC receiving ≥ 3 lines of chemotherapy (PPS ≥ 3)—The Gynecologic Cancer Intergroup (GCIG) Symptom Benefit Study (SBS).

Journal of Clinical Oncology ◽

10.1200/jco.2015.33.15_suppl.5536 ◽

2015 ◽

Vol 33 (15_suppl) ◽

pp. 5536-5536

Author(s):

Michael Friedlander ◽

Martin R. Stockler ◽

Rachel O'Connell ◽

Florence Joly ◽

Anne Lanceley ◽

...

Keyword(s):

Ovarian Cancer ◽

Clinical Trials ◽

Primary Endpoint ◽

Gynecologic Cancer ◽

Symptom Burden ◽

Resistant Refractory ◽

Platinum Sensitive ◽

Baseline predictors of early treatment failure in patients with platinum resistant/refractory (PRR) and potentially platinum sensitive (PPS ≥ 3) recurrent ovarian cancer (ROC) receiving ≥ 3 lines of chemotherapy: The Gynaecologic Cancer Intergroup (GCIG) Symptom Benefit Study (SBS).

Journal of Clinical Oncology ◽

10.1200/jco.2015.33.15_suppl.5564 ◽

2015 ◽

Vol 33 (15_suppl) ◽

pp. 5564-5564

Author(s):

Felicia T Roncolato ◽

Rachel O'Connell ◽

Florence Joly ◽

Anne Lanceley ◽

Felix Hilpert ◽

...

Keyword(s):

Ovarian Cancer ◽

Treatment Failure ◽

Early Treatment ◽

Early Treatment Failure ◽

Resistant Refractory ◽

Platinum Sensitive ◽

Platinum Resistant ◽

Gynaecologic Cancer

Efficacy and Safety of Niraparib Combined With Oral Etoposide in Platinum Resistant/Refractory Recurrent Ovarian Cancer

Case Medical Research ◽

10.31525/ct1-nct04217798 ◽

2020 ◽

Author(s):

Keyword(s):

Ovarian Cancer ◽

Oral Etoposide ◽

Efficacy And Safety ◽

Resistant Refractory ◽

Faculty Opinions recommendation of Phase I trial of a formulated IL-12 plasmid in combination with carboplatin and docetaxel chemotherapy in the treatment of platinum-sensitive recurrent ovarian cancer.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718040504.793483426 ◽

2013 ◽

Author(s):

Roberto Angioli

Keyword(s):

Ovarian Cancer ◽

Phase I ◽

Phase I Trial ◽

Platinum Sensitive ◽

Docetaxel Chemotherapy

Evidence-based chemotherapeutic management of potentially platinum-sensitive recurrent ovarian cancer

Therapy ◽

10.2217/thy.10.30 ◽

2010 ◽

Vol 7 (3) ◽

pp. 269-275 ◽

Cited By ~ 1

Author(s):

Maurie Markman

Keyword(s):

Ovarian Cancer ◽

Evidence Based ◽

Platinum Sensitive

510 Niraparib outcomes in brca wild-type platinum sensitive recurrent ovarian cancer: a comparison of real-world data to the nova trial

10.1136/ijgc-2020-esgo.146 ◽

2020 ◽

Author(s):

Douglas Cartwright ◽

Patricia Roxburgh ◽

Barbara Stanley ◽

Jennifer Brown ◽

Alistair Mclaren ◽

...

Keyword(s):

Ovarian Cancer ◽

Real World ◽

Wild Type ◽

Real World Data ◽

World Data ◽

Platinum Sensitive

Effects of PARP inhibitors therapy on the PFS and OS in platinum-sensitive recurrent ovarian cancer: A meta-analysis of randomized controlled trials

Gynecologic Oncology ◽

10.1016/j.ygyno.2019.04.630 ◽

2019 ◽

Vol 154 ◽

pp. 271

Author(s):

B.H. Min ◽

S.H. Yoon ◽

S.H. Shim

Keyword(s):

Ovarian Cancer ◽

Randomized Controlled Trials ◽

Meta Analysis ◽

Parp Inhibitors ◽

Controlled Trials ◽

Randomized Controlled ◽

Platinum Sensitive

Niraparib maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer and a time-to-progression after penultimate platinum-based chemotherapy of 6-12 or >12 months: a subgroup analysis of the phase III NORA trial

Gynecologic Oncology ◽

10.1016/s0090-8258(21)00681-8 ◽

2021 ◽

Vol 162 ◽

pp. S18

Author(s):

Qidan Huang ◽

Xiaohua Wu ◽

Jianqing Zhu ◽

Danqing Wang ◽

Jiaxin Yang ◽

...

Keyword(s):

Ovarian Cancer ◽

Maintenance Therapy ◽

Subgroup Analysis ◽

Phase Iii ◽

Time To Progression ◽

Platinum Sensitive ◽

Platinum Based Chemotherapy

Phase II trial of carboplatin and infusional cyclosporine in platinum-resistant recurrent ovarian cancer

Cancer Chemotherapy and Pharmacology ◽

10.1007/s00280-004-0818-x ◽

2004 ◽

Vol 54 (4) ◽

pp. 283-289 ◽

Cited By ~ 5

Author(s):

Robert J. Morgan ◽

Timothy W. Synold ◽

David Gandara ◽

Franco Muggia ◽

Sidney Scudder ◽

...

Keyword(s):

Ovarian Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Phase I trial of a formulated IL-12 plasmid in combination with carboplatin and docetaxel chemotherapy in the treatment of platinum-sensitive recurrent ovarian cancer

Gynecologic Oncology ◽

10.1016/j.ygyno.2013.07.081 ◽

2013 ◽

Vol 131 (1) ◽

pp. 169-173 ◽

Cited By ~ 34

Author(s):

Khursheed Anwer ◽

F. Joseph Kelly ◽

Christina Chu ◽

Jason G. Fewell ◽

Danny Lewis ◽

...

Keyword(s):

Ovarian Cancer ◽

Phase I ◽

Phase I Trial ◽

Platinum Sensitive ◽

Docetaxel Chemotherapy